ALBI Score Calculator: Objective Liver Function Assessment for HCC

The ALBI Score calculator on OncoToolkit-ALBI Score calculator provides a fast, objective way to quantify liver function in patients with hepatocellular carcinoma (HCC). By relying solely on albumin and bilirubin, it removes the subjectivity inherent in traditional liver scores and offers a standardized metric that can be used across clinics, trials, and multidisciplinary tumor boards. On our platform, the ALBI Score calculator transforms a logarithmic equation into an intuitive grade that clinicians can generate and interpret in seconds, directly at the point of care.¹, ², ³

As HCC management has become increasingly complex—with surgery, transplantation, locoregional therapies, and multiple systemic options—accurate characterization of hepatic reserve is critical. At OncoToolkit, we have built this calculator to reduce cognitive load and “calculator fatigue,” allowing hepatologists and HCC oncologists to focus on nuanced clinical decisions rather than on arithmetic and thresholds.², ⁴, ⁵

The Albumin–Bilirubin (ALBI) score is a continuous, laboratory-based index of liver function developed specifically for patients with HCC. It was proposed by Johnson and colleagues as an evidence-based alternative to the Child–Pugh classification, which mixes objective laboratories with subjective clinical assessments. ALBI uses only serum total bilirubin and albumin, both routinely measured in cirrhotic and HCC patients, to derive a prognostic score.⁶, ¹, ²

Treatment decisions in HCC often hinge on liver function as much as tumor burden, making robust hepatic assessment central to safe, effective care. The ALBI grade is clinically important because it:⁴, ⁵, ²

• Refines risk stratification within Child–Pugh A. ALBI can subdivide Child–Pugh A patients into groups with significantly different overall survival, revealing heterogeneity that Child–Pugh alone may not capture.⁵, ², ³, ⁷
• Supports therapy selection and sequencing. ALBI grade has been associated with outcomes after resection, ablation, TACE, radioembolization, and systemic treatments, helping clinicians anticipate treatment tolerance and prognosis.⁹, ¹⁰, ¹¹, ⁴, ⁵
• Enhances prognostic modeling. In multiple series, ALBI has matched or outperformed Child–Pugh for survival prediction, especially when used alongside tumor staging systems.², ³, ⁵

ALBI has been extensively validated across diverse HCC populations:

• Development and international validation cohorts. The original work included more than 6,000 patients from Asia, Europe, and North America, demonstrating good discrimination for overall survival and improved calibration compared to Child–Pugh.⁶, ¹, ²
• Surgical and curative-intent settings. Studies show that ALBI grade stratifies survival after hepatic resection or ablation, especially within Child–Pugh A, where it can identify patients at higher risk of postoperative complications and early mortality.³, ⁴, ⁷
• Locoregional therapies. In TACE and radioembolization cohorts, ALBI grade predicts survival, hepatic decompensation, and therapy-related mortality more accurately than Child–Pugh in many analyses.¹⁰, ⁴, ⁵, ⁹
• Systemic therapy and immunotherapy. Pre-treatment ALBI grade has been associated with outcomes in patients treated with sorafenib and newer systemic therapies, supporting its use in baseline risk assessment and trial stratification.¹¹, ⁴, ⁵

Typical endpoints include overall and progression-free survival, treatment-related liver failure, and early mortality, making ALBI a versatile marker across the HCC care continuum.⁴, ⁵, ²

Thoughtful use of ALBI requires awareness of its boundaries:

• No direct assessment of portal hypertension or encephalopathy. Because ALBI omits ascites, variceal status, and mental status, it should be interpreted alongside clinical examination, imaging, and occasionally other scores like Child–Pugh or MELD.⁵, ¹⁰, ²
• Heterogeneity within Grade 2. A large proportion of patients fall into Grade 2, prompting development of modified ALBI (mALBI) grades that further split this category into 2a and 2b for finer prognostic resolution.⁸, ¹⁵, ¹⁶
• Score does not dictate therapy. While ALBI is prognostic across many settings, treatment thresholds remain guided by broader guideline recommendations, institutional protocols, and patient-level factors.⁹, ⁴, ⁵

OncoToolkit therefore presents ALBI as a decision-support tool rather than a directive engine and encourages clinicians to integrate it with complementary assessments.

The workflow is intentionally simple:

1. Confirm you are in the ALBI tool. The header clearly indicates “ALBI Score – Liver / HCC,” minimizing the chance of using the wrong calculator.
2. Enter laboratory values.
   • Total bilirubin in µmol/L
   • Albumin in g/L The numeric controls are optimized for quick entry on both desktop and mobile.
3. Click “Calculate Score.” The platform immediately applies the published ALBI formula, rounding the calculated score for readability.
4. Review the result. The output panel displays:
   • The numeric ALBI score
   • The corresponding ALBI grade (1–3)
   • A qualitative risk label such as “Good prognosis,” “Intermediate prognosis,” or “Poor prognosis”

In everyday practice, the ALBI Score calculator can be used to:

• Frame initial HCC treatment discussions. At diagnosis, ALBI grade can be combined with tumor stage (e.g., BCLC) to anchor conversations about resection, transplant referral, locoregional therapies, or systemic treatment paths.², ⁴, ⁵
• Standardize MDT preparation. Before tumor boards, clinicians can quickly generate ALBI grades for each patient, ensuring consistent language when describing hepatic reserve and expected tolerance of proposed therapies.¹⁴
• Monitor hepatic trajectory over time. Repeating the calculator as labs evolve allows teams to track whether liver function is stable, improving, or decompensating under ongoing treatment.¹, ⁴

Because the tool focuses only on two widely available labs, it fits seamlessly into clinics with varied resource levels and is applicable globally.

Although the tool is not explicitly a board-prep module, its design supports teaching:

• Supervisors can walk fellows through how different bilirubin and albumin values translate into ALBI grades.
• The embedded reference table and visible formula help residents understand why certain “borderline” patients may still be considered high risk despite being Child–Pugh A.³, ⁷
• Nurse practitioners and physician associates can use the tool to become comfortable incorporating ALBI into patient counseling and care coordination.

Because the OncoToolkit implementation mirrors the original ALBI definition, scores generated from the calculator can be confidently used in research and QI projects:

• Retrospective analyses. Investigators can re-calculate ALBI for historical cohorts using stored labs and verify their calculations against the tool during data cleaning.¹⁷, ⁴
• Prospective registries. Standardized ALBI grading can be documented in case report forms or databases, facilitating pooled analyses and meta-analyses across centers.⁵, ¹, ²
• Quality dashboards. When combined with survival or toxicity tracking, ALBI provides a stable liver function variable for risk adjustment and outcomes benchmarking.¹³, ¹⁴